PT  - JOURNAL ARTICLE
AU  - HISAO IMAI
AU  - TAKEHITO SHUKUYA
AU  - TOSHIAKI TAKAHASHI
AU  - SAKAE FUJIWARA
AU  - KEITA MORI
AU  - AKIRA ONO
AU  - HIROAKI AKAMATSU
AU  - TETSUHIKO TAIRA
AU  - HIROTSUGU KENMOTSU
AU  - TATEAKI NAITO
AU  - KYOICHI KAIRA
AU  - HARUYASU MURAKAMI
AU  - HIDEYUKI HARADA
AU  - MASAHIRO ENDO
AU  - TAKASHI NAKAJIMA
AU  - NOBUYUKI YAMAMOTO
TI  - Comparison of the Time-to-response Between Radiotherapy and Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitors for Advanced Non-small Cell Lung Cancer with <em>EGFR</em> Mutation
DP  - 2013 Aug 01
TA  - Anticancer Research
PG  - 3279--3284
VI  - 33
IP  - 8
4099  - http://ar.iiarjournals.org/content/33/8/3279.short
4100  - http://ar.iiarjournals.org/content/33/8/3279.full
SO  - Anticancer Res2013 Aug 01; 33
AB  - Background: Patients harboring sensitive epidermal growth factor receptor (EGFR) mutations show a dramatic response to treatment with EGFR tyrosine kinase inhibitors (TKIs). However, there have been no clinical reports in lung cancer patients that compare the time-to-response between radiotherapy and EGFR-TKIs. Patients and Methods: We reviewed 17 and 32 consecutive patients with inoperable stage III/IV NSCLC who harbored sensitive EGFR mutations and who were treated with thoracic radiotherapy with or without chemotherapy and EGFR-TKIs, respectively. Results: There were statistically significant differences in time-to-partial response (PR) with regard to the treatment modalities (radiotherapy vs. EGFR-TKIs, median 57 days vs. 22 days, log-rank test, p=0.008). Conclusion: EGFR-TKIs elicit tumor shrinkage earlier than does radiotherapy in patients with a sensitive EGFR mutation, suggesting that EGFR-TKIs may be useful for early symptom improvement in these patients.